Diarrhoea in children still has a major impact on health-related social costs, affecting approximately 2 billion children younger than 5 years every year, and determining 2 million deaths, mostly in Africa and Asia.  According to WHO diarrhea consists in ≥3 passages of softened or liquid stools within 24 hours. Acute forms (duration 0-7 days) are traditionally defined in distinction with protracted (7-14 days) and chronic (>14 days) diarrhoea. ESPGHAN guidelines  state that acute gastroenteritis (AGE) does not generally require a specific diagnostic work-up. Microbiologic investigations should be limited to subjects with chronic diseases, in severely compromised conditions or with long-lasting symptoms that could be potentially eligible for specific treatments. The assessment of the degree of dehydration still remains the cornerstone of the management. Newborns and children aged less than 2 months, subjects with severe conditions, persistent vomit or massive diarrhea (>8 episodes/day) should be always clinically assessed. Hospital admission should be considered in cases of shock, severe dehydration, neurological abnormalities, intractable or bilious vomit, oral rehydration failure, when a surgical condition is suspected or when parental management at home does not represent a safe option. The distinction between bacterial and non-bacterial etiologies is not relevant to the treatment: the basic therapy is oral rehydration . Sometimes oral rehydration is not sufficient and i.v. fluids may be required (shock, altered level of consciousness, severe acidosis, failure of oral/enteral rehydration, persistent vomit, abdominal distension or ileus). In children, AGE treatment may include the use of several drugs (antiemetics, probiotics, anti-secretory drugs, gelatin tannate). Antiemetics decrease need for hospitalization, but may entail electrocardiographic alterations (i.e. prolonged QT interval) . A recent Cochrane review  concluded that probiotics may have a role in decreasing duration of diarrhoea of approximately one day, in reducing stool frequency during the second day and the risk of diarrhea lasting longer than 4 days. Even though some “strong recommendations” support the use of some specific strains (Lactobacillus GG and Saccharomyces boulardii), quality of evidence in favour of probiotics is generally low [4, 5]. Data regarding diosmectite and racecadotril should be carefully interpreted, as most of the available studies present major drawbacks [6, 7]. Finally, some evidence supports the use of gelatin tannate, a “mucosal regenerator” that creates a layer adhering to the intestinal wall which can protect against the penetration of aggressive bacteria [8, 9].
In accordance with article 5 of the Spanish Law RDL1/2015, the information set out in the following sections is intended for healthcare professionals.
Access to this information and all use which may be made thereof or of these contents is exclusive responsibility of those who use them. Noventure will not be held liable for any illegal or improper use or for the manipulation of the contents and information included in these pages.